There are currently 898 clinical trials in Minneapolis, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Minnesota, Hennepin County Medical Center, Abbott Northwestern Hospital and University of Minnesota/Masonic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
Recruiting
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
Gender:
ALL
Ages:
All
Trial Updated:
04/10/2024
Locations: Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota +1 locations
Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Register for Updates
Sugars in Cigarettes
NCT05308316
Recruiting
To investigate a comprehensive set of abuse liability and appeal measures, smoking intensity, as well as analyze the impact of sugar content on the formation in the oral cavity of smokers of DNA adducts derived from aldehydes and oxidative stress.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/03/2024
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota
Conditions: Tobacco Use
Register for Updates
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Abbott-Northwestern Hospital, Minneapolis, Minnesota +2 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
NCT04968548
Recruiting
This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
03/28/2024
Locations: University of Minnesota Health, Minneapolis, Minnesota
Conditions: Lung Cancer
Register for Updates
Veteran Support for Smoking Cessation Pilot Project (VAntage Pilot)
NCT04840108
Recruiting
This is a proposal to conduct a pilot study to assess the feasibility of recruitment of Veteran smoker and support person (SP) dyads and study procedures in preparation for a large randomized pragmatic trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Minneapolis Veterans Administration Health Care System, Minneapolis, Minnesota
Conditions: Smoking Cessation
Register for Updates
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
NCT04523727
Recruiting
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
Gender:
ALL
Ages:
Between 6 years and 16 years
Trial Updated:
03/12/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Hyperphosphatemia Related to Chronic Kidney Disease
Register for Updates
LOWER: Lomitapide Observational Worldwide Evaluation Registry
NCT02135705
Recruiting
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Gender:
ALL
Ages:
All
Trial Updated:
03/11/2024
Locations: Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
Conditions: Homozygous Familial Hypercholesterolemia
Register for Updates
Evaluation of the PrevisEA Device for Predicting Gastrointestinal Impairment
NCT04880473
Recruiting
PrevisEA is a noninvasive, disposable device that uses audio spectral analysis of sounds produced by the gastrointestinal tract to predict gastrointestinal impairment (GII). GII is most commonly associated with postoperative ileus (POI), but could be the result of other causes, such as early postoperative bowel obstruction. GII is defined as failure of successful early oral re-feeding in a subject undergoing major abdominal surgery. For subjects who are allowed to resume a diet during the first... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/11/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Gastrointestinal Complication
Register for Updates
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
NCT04626791
Recruiting
This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line therapy work in treating transplant-eligible patients with mantle cell lymphoma. Modified VR-CAP is a combination of drugs used as standard first line treatment for mantle cell lymphoma. Chemotherapy drugs, such as bortezomib, cyclophosphamide, doxorubicin hydrochloride, and cytarabine hydrochlorid... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/08/2024
Locations: Metropolitan-Mount Sinai Medical Center, Minneapolis, Minnesota
Conditions: Mantle Cell Lymphoma
Register for Updates
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567
Recruiting
The study is an extension of two parent studies (MLN0002-3024 \[NCT04779307\] and MLN0002-3025 \[NCT04779320\]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
03/05/2024
Locations: MNGI Digestive Health PA-Plymouth, Minneapolis, Minnesota
Conditions: Ulcerative Colitis, Crohn's Disease
Register for Updates
CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults
NCT06305910
Recruiting
This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat malignant glioma in children and young adults. The primary objective of this study is to determine the maximum tolerated dose (MTD) of CD200AR-L when given with a fixed dose of GBM6-AD vaccine, imiquimod, and a single dose of radiation for patients with recurrent High Grade Glioma (HGG) or following standard of care therapy radiation the... Read More
Gender:
ALL
Ages:
Between 2 years and 25 years
Trial Updated:
03/05/2024
Locations: Children's Minnesota, Minneapolis, Minnesota
Conditions: Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
Register for Updates
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
NCT05130866
Recruiting
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
02/29/2024
Locations: University of Minnesota / Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Neurofibromatosis Type 2
Register for Updates